Table 1. Study population characteristics stratified by HPV16 E2 gene status and tumor site.
| Oropharynx3, n = 31 | |||||||
| Intact E2 | Disrupted E2 | p value* | Deletions | ||||
| n = 21 (68%) | n = 7 (22%) | 0.011 | n = 3 (10%) | ||||
| Age at diagnosis in years | |||||||
| <60 | 12 | 57% | 3 | 43% | 0.4 | 0 | 0% |
| ≥60 | 9 | 43% | 4 | 57% | 3 | 100% | |
| Sex | |||||||
| Men | 18 | 86% | 6 | 86% | 1 | 1 | 33% |
| Women | 3 | 14% | 1 | 14% | 2 | 67% | |
| Smoking Status2 | |||||||
| Current Smoker | 5 | 24% | 3 | 43% | 0.42 | 1 | 33% |
| Ex-smoker | 12 | 57% | 2 | 29% | 1 | 33% | |
| Never Smoker | 4 | 19% | 2 | 29% | 1 | 33% | |
| Overall Stage | |||||||
| I–II | 3 | 14% | 1 | 14% | 1 | 1 | 33% |
| III–IV | 18 | 86% | 6 | 86% | 2 | 67% | |
| Nodal Stage n (%) | |||||||
| N0 | 3 | 14% | 1 | 14% | 0.8 | 1 | 33% |
| N1 | 1 | 5% | 0 | 0% | 0 | 0% | |
| N2 | 14 | 67% | 4 | 57% | 2 | 67% | |
| N3 | 3 | 14% | 2 | 29% | 0 | 0% | |
| Tumor Size n (%) | |||||||
| T1–T2 | 17 | 81% | 4 | 57% | 0.32 | 2 | 67% |
| T3–T4 | 4 | 19% | 3 | 43% | 1 | 33% |
|
| Anatomical Site3, n (%) | |||||||
| Tonsil | 14 | 67% | 2 | 29% | 0.05 | 2 | 67% |
| Base of Tongue | 6 | 28% | 2 | 29% | 1 | 33% |
|
| Oropharyngeal Wall | 0 | 0% | 2 | 29% | |||
| Not Specified | 1 | 5% | 1 | 14% | |||
| Non-oropharynx, n = 17 | |||||||
| Intact E2 | Disrupted E2 | p value* | Deletions | ||||
| Age at diagnosis in years | n = 5 (29%) | n = 10 (59%) | 0.011 | n = 2 (12%) | |||
| <60 | 3 | 60% | 6 | 60% | 0.61 | 1 | 50% |
| ≥60 | 2 | 40% | 4 | 40% | 1 | 50% | |
| Sex, n (%) | |||||||
| Men | 4 | 80% | 7 | 70% | 1 | 2 | 100% |
| Women | 1 | 20% | 3 | 30% | 0 | 0% | |
| Smoking Status2 | |||||||
| Current Smoker | 1 | 20% | 5 | 50% | 0.47 | 0 | 0% |
| Ex-smoker | 3 | 60% | 3 | 30% | 2 | 100% | |
| Never Smoker | 1 | 20% | 2 | 20% | 0 | 0% | |
| Overall Stage | |||||||
| I–II | 1 | 20% | 2 | 20% | 1 | 0 | 0% |
| III–IV | 4 | 80% | 8 | 80% | 2 | 100% | |
| Nodal Stage n (%) | |||||||
| N0 | 2 | 40% | 4 | 40% | 0.49 | 0 | 0% |
| N1 | 1 | 20% | 2 | 20% | 0 | 0% | |
| N2 | 1 | 20% | 4 | 40% | 2 | 100% | |
| N3 | 1 | 20% | 0 | 0% | 0 | 0% | |
| Tumor Size n (%) | |||||||
| T1–T2 | 3 | 60% | 4 | 40% | 0.61 | 0 | 0% |
| T3–T4 | 2 | 40% | 6 | 60% | 2 | 100% | |
| Anatomical Site3, n (%) | |||||||
| Oral Cavity | 1 | 20% | 4 | 40% | 74 | 0 | 0% |
| Larynx | 2 | 40% | 3 | 30% | 1 | 50% | |
| Hypopharynx | 2 | 40% | 3 | 30% | 0 | 0% | |
| Nasopharynx | 0 | 0% | 0 | 0% | 1 | 50% | |
*p-Value for 2-sided Fisher exact test. Row numbers may not sum to column totals due to missing data.
1p-value determined by Fisher exact or Chi-square test on results from intact and disrupted E2 status for oropharynx and non-oropharynx.
2Smoking status was defined as never smoked, exsmoker (at time of diagnosis) and current smoker
3Oropharynx includes: base of tongue, tonsil, soft palate, oropharyngeal wall, uvula and oropharynx-NOS. Hypopharynx includes: posterior pharyngeal wall, pyriform sinus and hypopharynx-NOS. Larynx includes glottis, supraglottis-aryepiglottic fold and epiglottis. Oral cavity includes buccal, alveolar ridge, anterior tongue, floor of mouth, hard palate, inner lip mucosa and retromolar trigone.